Survodutide (BI 456906) is an investigational, once-weekly injectable drug, a dual agonist for glucagon and GLP-1 receptors, developed by Boehringer Ingelheim for treating obesity, overweight, and Metabolic Dysfunction-Associated Steatohepatitis (MASH, formerly fatty liver disease), showing promise in weight loss, liver fat reduction, glycemic control, and cardiovascular risk factors. It’s currently in Phase 3 trials (SYNCHRONIZE, LIVERAGE) and has received U.S. FDA Breakthrough Therapy designation for MASH, with potential approval in 2027 if trials succeed.
How it works
-
Dual Action:Activates both GLP-1 and glucagon receptors, which regulate metabolism, appetite, and energy use.
-
Metabolic Benefits:Increases energy expenditure, decreases food intake, improves liver health (reducing fat and fibrosis), and helps control blood sugar.
-
Unique Design:It’s designed with a strong bias for GLP-1 receptor activation for weight loss but also leverages glucagon’s direct effects on the liver.
Key indications
- Obesity & Overweight: Proven effective for significant weight reduction.
- MASH: Shows promise in reducing liver fat and fibrosis, even in patients with cirrhosis, a serious form of fatty liver disease.
- Cardiovascular Health: Demonstrates reductions in blood pressure and triglycerides.
Development status
- Phase 3 Trials: Underway globally for obesity (SYNCHRONIZE studies) and MASH (LIVERAGE studies).
- FDA Designations: Holds Breakthrough Therapy designation for MASH.
- Availability: Not yet on the market; expected around 2027 if trials are successful, with results anticipated in early 2026.
Reviews
There are no reviews yet.